Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07594847
PHASE1

A Study of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects

Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

The aim of this trial is to evaluate the effect of a single oral dose of HDM1002 tablets on the QT/QTc interval in healthy subjects.

Official title: A Phase I, Single-center, Randomized, Double-blind, Placebo- and Positive-controlled, Four-period, Crossover Clinical Study to Evaluate the Effect of HDM1002 Tablets on Cardiac Repolarization in Healthy Subjects

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

72

Start Date

2026-03-07

Completion Date

2026-11-06

Last Updated

2026-05-19

Healthy Volunteers

Yes

Interventions

DRUG

HDM1002 200 mg

HDM1002 tablet, oral, 200 mg single dose

DRUG

HDM1002 400 mg

HDM1002 tablet, oral, 400 mg single dose

DRUG

Placebo

Placebo tablet, oral, single dose

DRUG

Moxifloxacin 400 mg

Moxifloxacin tablet, oral, 400 mg single dose

Locations (1)

PKUcare Luzhong Hospital

Zibo, Shangdong, China